Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00526474
Status:
COMPLETED
Last Update Posted:
2018-09-21
First Post:
2007-09-06
Brief Title:
Trial to Assess the Effects of Vorapaxar SCH 530348 MK-5348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis TRA 2P - TIMI 50 P04737
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events TRA 2P - TIMI 50
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to determine whether vorapaxar when added to the existing standard of care SOC for preventing heart attack and stroke eg aspirin clopidogrel in participants with a known history of atherosclerosis will yield additional benefit over the existing standard of care without vorapaxar in preventing heart attack and stroke
The study is also designed to assess risk of bleeding with vorapaxar added to the standard of care versus the standard of care alone
The study is also designed to assess risk of bleeding with vorapaxar added to the standard of care versus the standard of care alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-5348-015 | OTHER | Merck Study Number | None |
| TRA 2P - TIMI 50 | None | None | None |
| 2006-002942-12 | None | None | None |